Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC.ADIL · Entity 7742 | Director | April 07, 2026 | April 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADIAL PHARMACEUTICALS, INC.
Report date April 07, 2026 · Filed April 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,185 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Grant · Acquired 9,185 · Balance 9,185 F1: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2026 Filed Apr 9, 2026 21:00 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantCommon Stock | 9,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-042051 · ownership.xml · nonDerivative · entry 1 Gilliland Robertson H. · CIK 0001718351 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,185 F1 · shares: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:01 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001213900-25-050021 · ownership.xml · derivative · entry 1 Gilliland Robertson H. · CIK 0001718351 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2035-05-28 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 22:21 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001213900-24-026725 · ownership.xml · derivative · entry 1 Gilliland Robertson H. · CIK 0001718351 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2034-03-24 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024. Read SEC document |
| May 23, 2023 Filed May 25, 2023 20:38 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001213900-23-043114 · ownership.xml · derivative · entry 1 Gilliland Robertson H. · CIK 0001718351 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-05-23 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 19:55 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option · Derivative | 40,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001213900-22-009422 · ownership.xml · derivative · entry 1 Gilliland Robertson H. · CIK 0001718351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-02-22 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:48 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option · Derivative | 40,000 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001213900-21-008158 · ownership.xml · derivative · entry 1 Gilliland Robertson H. · CIK 0001718351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-07 F1 · shares: The option vests pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months. Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 00:22 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option · Derivative | 60,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001213900-20-005549 · ownership.xml · derivative · entry 1 Gilliland Robertson H. · CIK 0001718351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-02 F1 · shares: These options vest pro rata on a monthly basis over 36 months. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:03 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseWarrant to purchase common stock · Derivative | 14,000 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010083 · ownership.xml · derivative · entry 5 Gilliland Robertson H. · CIK 0001718351 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Keller Enterprises, LLC Disclosed balance after: 43,931 Underlying: Common Stock · 43,931 shares Expires 2023-07-31 F3 · shares: On July 31, 2018, Keller purchased 14,000 units (the "Units") in the initial public offering of the issuer at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the IPO. F3 · price: On July 31, 2018, Keller purchased 14,000 units (the "Units") in the initial public offering of the issuer at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the IPO. F2 · ownership.nature: Mr. Gilliland is the principal of Keller Enterprises, LLC ("Keller"). Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:03 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionWarrant to purchase common stock · Derivative | 29,931 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010083 · ownership.xml · derivative · entry 4 Gilliland Robertson H. · CIK 0001718351 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Keller Enterprises, LLC Disclosed balance after: 29,931 Underlying: Common Stock · 29,931 shares Expires 2023-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 at a conversion price of $0.44 per share upon consummation of the initial public offering of the issuer on July 31, 2018. F2 · ownership.nature: Mr. Gilliland is the principal of Keller Enterprises, LLC ("Keller"). Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:03 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionConvertible Note · Derivative | 29,931 | Not disclosed Strike: $0.44 | Not disclosed |
DisclosureSEC source: 0001213900-18-010083 · ownership.xml · derivative · entry 3 Gilliland Robertson H. · CIK 0001718351 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Keller Enterprises, LLC Disclosed balance after: 0 Underlying: Common Stock · 29,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 at a conversion price of $0.44 per share upon consummation of the initial public offering of the issuer on July 31, 2018. F1 · derivative.exercise_date: The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 at a conversion price of $0.44 per share upon consummation of the initial public offering of the issuer on July 31, 2018. F1 · derivative.expiration_date: The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 at a conversion price of $0.44 per share upon consummation of the initial public offering of the issuer on July 31, 2018. F2 · ownership.nature: Mr. Gilliland is the principal of Keller Enterprises, LLC ("Keller"). Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:03 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 14,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010083 · ownership.xml · nonDerivative · entry 2 Gilliland Robertson H. · CIK 0001718351 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Keller Enterprises, LLC Disclosed balance after: 109,424 F3 · shares: On July 31, 2018, Keller purchased 14,000 units (the "Units") in the initial public offering of the issuer at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the IPO. F3 · price: On July 31, 2018, Keller purchased 14,000 units (the "Units") in the initial public offering of the issuer at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the IPO. F2 · ownership.nature: Mr. Gilliland is the principal of Keller Enterprises, LLC ("Keller"). Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:03 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionCommon Stock | 29,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010083 · ownership.xml · nonDerivative · entry 1 Gilliland Robertson H. · CIK 0001718351 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Keller Enterprises, LLC Disclosed balance after: 95,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 at a conversion price of $0.44 per share upon consummation of the initial public offering of the issuer on July 31, 2018. F2 · ownership.nature: Mr. Gilliland is the principal of Keller Enterprises, LLC ("Keller"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.